Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey.

Litzelman K, Keller AO, Tevaarwerk A, DuBenske L.

J Gen Intern Med. 2018 Jun;33(6):869-876. doi: 10.1007/s11606-018-4331-z. Epub 2018 Feb 5.

PMID:
29404942
2.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.

Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM.

NPJ Breast Cancer. 2018 Jan 11;4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018. Review.

3.

Breast cancer survivor's perspectives on the role different providers play in follow-up care.

Tucholka JL, Jacobson N, Steffens NM, Schumacher JR, Tevaarwerk AJ, Anderson B, Wilke LG, Greenberg CC, Neuman HB.

Support Care Cancer. 2018 Jun;26(6):2015-2022. doi: 10.1007/s00520-018-4042-3. Epub 2018 Jan 13.

PMID:
29332175
4.

Cancer Survivorship Care Plan Utilization and Impact on Clinical Decision-Making at Point-of-Care Visits with Primary Care: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.

Donohue S, Haine JE, Li Z, Feldstein DA, Micek M, Trowbridge ER, Kamnetz SA, Sosman JM, Wilke LG, Sesto ME, Tevaarwerk AJ.

J Cancer Educ. 2017 Nov 2. doi: 10.1007/s13187-017-1295-3. [Epub ahead of print]

PMID:
29098650
5.

The Impact of a Primary Care Education Program Regarding Cancer Survivorship Care Plans: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.

Donohue S, Haine JE, Li Z, Trowbridge ER, Kamnetz SA, Feldstein DA, Sosman JM, Wilke LG, Sesto ME, Tevaarwerk AJ.

J Cancer Educ. 2017 Sep 20. doi: 10.1007/s13187-017-1281-9. [Epub ahead of print]

PMID:
28932992
6.

Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR.

J Natl Compr Canc Netw. 2017 Sep;15(9):1140-1163. doi: 10.6004/jnccn.2017.0146.

7.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
8.

Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers.

Tevaarwerk AJ, Hocking WG, Zeal JL, Gribble M, Seaborne L, Buhr KA, Wisinski KB, Burkard ME, Wiegmann DA, Sesto ME.

J Oncol Pract. 2017 May;13(5):e486-e495. doi: 10.1200/JOP.2016.018648. Epub 2017 Feb 21.

9.

Work-related barriers, facilitators, and strategies of breast cancer survivors working during curative treatment.

Sun W, Chen K, Terhaar A, Wiegmann DA, Heidrich SM, Tevaarwerk AJ, Sesto ME.

Work. 2016;55(4):783-795. doi: 10.3233/WOR-162449.

10.

Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.

Tevaarwerk AJ, Wisinski KB, O'Regan RM.

J Oncol Pract. 2016 Nov;12(11):1148-1156. Review.

PMID:
27858538
11.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ.

Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8.

12.

Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care.

Neuman HB, Jacobs EA, Steffens NM, Jacobson N, Tevaarwerk A, Wilke LG, Tucholka J, Greenberg CC.

Cancer Med. 2016 Sep;5(9):2198-204. doi: 10.1002/cam4.793. Epub 2016 Jun 30.

13.

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.

Wisinski KB, Xu W, Tevaarwerk AJ, Saha S, Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, Harter J, Burkard ME.

Clin Breast Cancer. 2016 Aug;16(4):256-61. doi: 10.1016/j.clbc.2016.03.005. Epub 2016 Mar 31.

14.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G.

Clin Cancer Res. 2016 Jun 1;22(11):2659-67. doi: 10.1158/1078-0432.CCR-15-2365. Epub 2016 Mar 29.

15.

Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.

Tevaarwerk AJ, Lee JW, Terhaar A, Sesto ME, Smith ML, Cleeland CS, Fisch MJ.

Cancer. 2016 Feb 1;122(3):438-46. doi: 10.1002/cncr.29656. Epub 2015 Dec 21.

16.

Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians.

Mirrielees JA, Breckheimer KR, White TA, Denure DA, Schroeder MM, Gaines ME, Wilke LG, Tevaarwerk AJ.

J Cancer Educ. 2017 Mar;32(1):97-104. doi: 10.1007/s13187-015-0932-y.

17.

Oncologists' Perspectives of Their Roles and Responsibilities During Multi-disciplinary Breast Cancer Follow-Up.

Neuman HB, Steffens NM, Jacobson N, Tevaarwerk A, Anderson B, Wilke LG, Greenberg CC.

Ann Surg Oncol. 2016 Mar;23(3):708-14. doi: 10.1245/s10434-015-4904-6. Epub 2015 Oct 16.

18.

Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.

Andreason M, Zhang C, Onitilo AA, Engel J, Ledesma WM, Ridolfi K, Kim K, Charlson JC, Wisinski KB, Tevaarwerk AJ.

J Community Support Oncol. 2015 May;13(5):195-201. doi: 10.12788/jcso.0135. No abstract available.

19.

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM.

Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65. doi: 10.2146/ajhp140591.

20.

Evaluating primary care providers' views on survivorship care plans generated by an electronic health record system.

Donohue S, Sesto ME, Hahn DL, Buhr KA, Jacobs EA, Sosman JM, Andreason MJ, Wiegmann DA, Tevaarwerk AJ.

J Oncol Pract. 2015 May;11(3):e329-35. doi: 10.1200/JOP.2014.003335. Epub 2015 Mar 24.

21.

Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer.

Ehsani S, Strigel RM, Pettke E, Wilke L, Tevaarwerk AJ, DeMartini WB, Wisinski KB.

Breast J. 2015 May-Jun;21(3):246-53. doi: 10.1111/tbj.12396. Epub 2015 Mar 17.

22.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ.

J Clin Oncol. 2014 Dec 10;32(35):3948-58. doi: 10.1200/JCO.2014.55.6993. Epub 2014 Oct 27.

23.

A multicenter phase 1 study of ╬│ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17.

24.

Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles.

Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA.

Sci Transl Med. 2014 Mar 26;6(229):229ra43. doi: 10.1126/scitranslmed.3007965.

25.

Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study.

Tevaarwerk AJ, Wisinski KB, Buhr KA, Njiaju UO, Tun M, Donohue S, Sekhon N, Yen T, Wiegmann DA, Sesto ME.

J Oncol Pract. 2014 May;10(3):e150-9. doi: 10.1200/JOP.2013.001115. Epub 2014 Feb 11.

26.

Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer).

Rocque GB, Wisinski KB, Buhr KA, Froeschner JL, Jones N, Donohue S, Wiegmann D, Sesto ME, Tevaarwerk AJ.

J Cancer Educ. 2014 Jun;29(2):270-7. doi: 10.1007/s13187-013-0591-9.

27.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ.

Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

28.

Employment and retirement status of older cancer survivors compared to non-cancer siblings.

Sesto ME, Faatin M, Wang S, Tevaarwerk AJ, Wiegmann DA.

Work. 2013;46(4):445-53. doi: 10.3233/WOR-131680.

29.

Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.

Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D.

Oncologist. 2013;18(4):353-61. doi: 10.1634/theoncologist.2012-0261. Epub 2013 Feb 12.

30.

Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study.

Tevaarwerk AJ, Lee JW, Sesto ME, Buhr KA, Cleeland CS, Manola J, Wagner LI, Chang VT, Fisch MJ.

J Cancer Surviv. 2013 Jun;7(2):191-202. doi: 10.1007/s11764-012-0258-2. Epub 2013 Feb 2.

31.

Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.

Njiaju UO, Tevaarwerk AJ, Kim K, Chang JE, Hansen RM, Champeny TL, Traynor AM, Meadows S, Van Ummersen L, Powers K, Stewart JA.

Cancer Chemother Pharmacol. 2013 Mar;71(3):613-8. doi: 10.1007/s00280-012-2044-2. Epub 2012 Dec 11.

32.

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA.

Cancer. 2013 Mar 15;119(6):1140-8. doi: 10.1002/cncr.27819. Epub 2012 Oct 12.

33.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

34.

Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME.

Breast Cancer Res Treat. 2012 Jan;131(2):713-21. doi: 10.1007/s10549-011-1862-y. Epub 2011 Nov 8.

35.

Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience.

Loconte NK, Williamson A, Gayle A, Weiss J, Leal T, Cetnar J, Mohammed T, Tevaarwerk A, Jones N.

J Gastrointest Oncol. 2011;2(2):85-92. No abstract available.

36.

Persistence in breast cancer disparities between African Americans and whites in Wisconsin.

Lepeak L, Tevaarwerk A, Jones N, Williamson A, Cetnar J, LoConte N.

WMJ. 2011 Feb;110(1):21-5.

37.

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.

Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G.

Invest New Drugs. 2012 Jun;30(3):1039-45. doi: 10.1007/s10637-010-9629-6. Epub 2011 Jan 12.

38.

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.

Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D.

Clin Breast Cancer. 2010 Dec 1;10(6):471-6. doi: 10.3816/CBC.2010.n.062.

39.

In the interest of full disclosure.

Burkard ME, Tevaarwerk AJ, Wisinski KB.

Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9. No abstract available.

PMID:
20359661
40.
41.

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G.

Clin Cancer Res. 2009 Feb 15;15(4):1460-5. doi: 10.1158/1078-0432.CCR-08-1599.

42.

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.

Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G.

Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51. doi: 10.1007/s00280-008-0844-1. Epub 2008 Oct 8.

43.

Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci.

Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA.

J Immunol. 2000 Apr 1;164(7):3919-23.

Supplemental Content

Loading ...
Support Center